Newsroom | 5192 results

MANHASSET, N.Y.--(BUSINESS WIRE)--In recognition of their impact on society through the successful production, patenting and commercialization of groundbreaking technologies, four esteemed scientists from Northwell Health’s Feinstein Institutes for Medical Research – Lior Brimberg, PhD; Jared M. Huston, MD; Stavros Zanos, MD, PhD; and Theodoros Zanos, PhD – have been named to the prestigious 2026 class of Senior Members by the National Academy of Inventors (NAI). This significant recognition hi...

SALT LAKE CITY--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in Implantable Tibial Neuromodulation (ITNM) and developer of the Revi® System, a patient-centric solution for urgency urinary incontinence (UUI), today announced that three-year results from the pivotal OASIS study were presented by Roger Dmochowski, M.D., Chief Medical Officer, BlueWind Medical, at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2026 Winter Meeting. The data confirm Rev...

GENF--(BUSINESS WIRE)--Das Wyss Center for Bio and Neuroengineering Geneva gab heute den erfolgreichen Abschluss der Startkapital-Finanzierungsrunde für Clee Medical SA bekannt, ein Schweizer Spin-off-Unternehmen im Bereich Neurotechnologie, das ultrahochauflösende Echtzeit-Bildgebung für die Gehirnchirurgie entwickelt. Die Runde wurde vom High-Tech Gründerfonds (HTGF) angeführt, unter Beteiligung der Zürcher Kantonalbank (ZKB), Kickfund, FONGIT und Venture Kick, die sich den bestehenden Invest...

GINEBRA, Suiza--(BUSINESS WIRE)--Wyss Center for Bio and Neuroengineering Geneva anunció hoy el cierre exitoso de la ronda de financiación semilla de Clee Medical SA, una empresa derivada de neurotecnología suiza que desarrolla imágenes intraoperatorias en tiempo real de alta resolución para cirugías cerebrales. La ronda fue liderada por High-Tech Gründerfonds (HTGF) y contó con la participación de Zürcher Kantonalbank (ZKB), Kickfund, FONGIT y Venture Kick, que se unieron a los inversores exis...

GINEVRA--(BUSINESS WIRE)--Il Wyss Center for Bio and Neuroengineering Geneva oggi ha annunciato la riuscita chiusura del round di finanziamento iniziale (seed) di Clee Medical SA, spin-off neurotecnologico svizzero impegnato nello sviluppo di soluzioni ad altissima risoluzione per l'imaging intraoperatorio in tempo reale destinate al settore della chirurgia cerebrale. Il round era guidato da High-Tech Gründerfonds (HTGF) con la partecipazione di Zürcher Kantonalbank (ZKB), Kickfund, FONGIT e di...

GENÈVE--(BUSINESS WIRE)--Het Wyss Center for Bio and Neuroengineering Geneva heeft vandaag bekendgemaakt dat de seed-financieringsronde van Clee Medical SA, een Zwitserse spin-off op het gebied van neurotechnologie die realtime intraoperatieve beeldvorming met ultrahoge resolutie voor hersenchirurgie ontwikkelt, succesvol is afgerond. De ronde werd geleid door High-Tech Gründerfonds (HTGF), met deelname van Zürcher Kantonalbank (ZKB), Kickfund, FONGIT en Venture Kick, die zich aansloten bij bes...

GENÈVE,--(BUSINESS WIRE)--Le « Wyss Center for Bio and Neuroengineering Geneva » a annoncé aujourd'hui la clôture réussie du tour de table d'amorçage de Clee Medical SA, une spin-off suisse de neurotechnologies développant une imagerie peropératoire en temps réel à ultra-haute résolution pour la chirurgie cérébrale. Ce tour de table a été mené par High-Tech Gründerfonds (HTGF), avec la participation de la Banque cantonale de Zurich (ZKB), de Kickfund, de FONGIT et de Venture Kick, qui rejoignen...

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported its full-year 2025 financial results and provided business updates. “We are proud of the strong execution and momentum across our organization, following a year of significant progress in our comprehensive development program...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NGN-401, an investigational gene therapy in late-stage clinical development as a potential best-in-class treatment for Rett syndrome. The Breakthrough Therapy designation was based on the F...

MANHASSET, N.Y.--(BUSINESS WIRE)--What if there was a switch in the brain that could turn on or off the body’s physical response to stress? New research from scientists at Northwell Health's Feinstein Institutes for Medical Research has identified a specific brain circuit that acts as a control center for both inflammation and stress responses. Published today in the Journal of Experimental Medicine, the study shows that a specific group of brain cells are capable of controlling inflammation an...